Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ITRM 
Iterum Therapeutics PLC (ITRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ITRM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 38.99% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.40M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 3.23 | 52 Weeks Range 0.61 - 3.02 | Updated Date 10/17/2025 |
52 Weeks Range 0.61 - 3.02 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.81 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.16% | Return on Equity (TTM) -555.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 49438729 | Price to Sales(TTM) 1349.79 |
Enterprise Value 49438729 | Price to Sales(TTM) 1349.79 | ||
Enterprise Value to Revenue 105.22 | Enterprise Value to EBITDA 0.55 | Shares Outstanding 48051157 | Shares Floating 44245169 |
Shares Outstanding 48051157 | Shares Floating 44245169 | ||
Percent Insiders 0.92 | Percent Institutions 8.58 |
Upturn AI SWOT
Iterum Therapeutics PLC
Company Overview
History and Background
Iterum Therapeutics PLC is a pharmaceutical company focused on developing and commercializing anti-infectives to treat multi-drug resistant infections. Founded in 2015, they aim to address the growing problem of antibiotic resistance.
Core Business Areas
- Anti-infective Development: Developing and commercializing sulopenem etzadroxil/probenecid, an oral antibiotic to treat uncomplicated urinary tract infections (uUTI) and other infections caused by multi-drug resistant bacteria.
Leadership and Structure
Corey Fishman is the Chief Executive Officer. The company has a board of directors overseeing its operations.
Top Products and Market Share
Key Offerings
- Sulopenem: Sulopenem is Iterum's primary product; a novel penem antibiotic. It is designed to be an oral treatment for infections caused by multi-drug resistant bacteria, initially targeting uUTIs. As of late 2023, sulopenem has not yet been approved by the FDA. Competitors include existing IV antibiotics (e.g., carbapenems) and oral antibiotics (e.g., fluoroquinolones, trimethoprim/sulfamethoxazole) that are facing increasing resistance.
Market Dynamics
Industry Overview
The anti-infectives market is driven by the increasing prevalence of antibiotic-resistant bacteria. There is a growing need for new antibiotics to combat these resistant infections.
Positioning
Iterum aims to offer an oral alternative to intravenous antibiotics for certain infections. Their competitive advantage lies in potentially offering a more convenient and cost-effective treatment option.
Total Addressable Market (TAM)
The TAM for uncomplicated urinary tract infections (uUTI) is significant, representing a large patient population. Iterum is positioned to capture a portion of this market by providing an oral treatment option for resistant strains. Exact market value is difficult to pinpoint due to competition and pricing pressures, but approximates USD 5 Billion annually.
Upturn SWOT Analysis
Strengths
- Novel oral antibiotic candidate
- Addresses unmet need for resistant infections
- Experienced management team
Weaknesses
- Reliance on a single product candidate (Sulopenem)
- Dependence on regulatory approval (FDA)
- Limited financial resources
- History of FDA rejection
Opportunities
- Potential for expansion to other indications
- Partnerships with larger pharmaceutical companies
- Government incentives for antibiotic development
- Growing awareness of antibiotic resistance
Threats
- Regulatory hurdles and delays
- Competition from existing antibiotics and new entrants
- Changes in reimbursement policies
- Development of new resistance mechanisms
Competitors and Market Share
Key Competitors
- PFE
- MRK
- ABBV
- RDHL
Competitive Landscape
Iterum faces significant competition from established pharmaceutical companies with broad product portfolios. Their success hinges on Sulopenem's efficacy and market acceptance.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's pre-commercial stage.
Future Projections: Future growth depends on regulatory approval and successful commercialization of Sulopenem. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include seeking FDA approval for Sulopenem and exploring potential partnerships.
Summary
Iterum Therapeutics is a high-risk, high-reward pharmaceutical company focused on developing an oral antibiotic to combat multi-drug resistant infections. Their future hinges on regulatory approval and successful commercialization of Sulopenem. The company faces significant financial challenges and competition from established players. Approval of sulopenem is crucial to its long-term survival. Iterum needs to carefully manage its finances while pursuing FDA approval.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
- Yahoo Finance
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and thorough research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Iterum Therapeutics PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-05-25 | President, CEO & Director Mr. Corey N. Fishman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://www.iterumtx.com |
Full time employees 9 | Website https://www.iterumtx.com | ||
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.